HDAC9 and ovarian cancer: In both in vitro (cisplatin-resistant ovarian cancer cells) and in vivo (xenografts), Steele et al. [93] observed that the combination of decitabine and a clinically relevant inhibitor of HDAC activity (belinostat) increased the expression of epigenetically silenced MLH1 gene and MAGE-A1 antigen when compared with decitabine alone.